Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clin... (ne loss. Our drug development pr...)

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

Date:5/14/2009

ne loss.

"Our drug development program focuses on a different molecular target," said Colca. "We believe that selective activation of the novel mitochondrial target will produce a significantly improved safety profile for individuals with type 2 diabetes. If the results of this study can be successfully extended to longer trials, we might be able to achieve our long-term goal of a therapeutic option that could be used early in the course of the disease to prevent the otherwise inexorable progression of diabetes and its complications."

Colca and Rolf Kletzien, two West Michigan scientists who are developing the MSDC drug portfolio of more than 100 analogs, have spent much of their careers working on treatments for type 2 diabetes. Colca also was instrumental in the early development of pioglitazone, the active ingredient in Actos, during his tenure with Upjohn Company.

"We are pleased that our lead compound performed so well in the Phase IIa study," said Mark Olesnavage, chief executive officer of MSDC. "The preliminary Phase IIa results match our pre-clinical studies that suggested that this compound can deliver significant metabolic benefit without some of the complications inherent in current therapies."

Additional safety and expanded efficacy data will be gathered in a 90-day, multinational Phase IIb study that is planned for late 2009.

According to the American Diabetes Association, approximately $1 in every 10 health care dollars spent is attributed to diabetes. While an estimated 17.9 million Americans have been diagnosed with diabetes, 6.3 million people (or nearly one in four) are unaware that they have the disease.

There were 1.6 million new cases of diabetes in the United States during 2007. This growth rate of 7 percent continues to outpace the population growth and has been described by many health care professionals as an epidemic.

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
2. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
3. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
4. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
5. NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
6. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
10. MedNet Solutions to Share Industry Expertise at the 13th Annual EDC & Beyond Conference in Orlando, FL
11. Facet Solutions, Inc. Expands U.S. Pivotal Study With Next Generation Implant System

Post Your Comments:

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clin...(ne loss. Our drug development pr...),Health